The prevalence of HIV-associated neurocognitive disorder (HAND) is increasing. The presence of HAND is a risk factor for work disability, poor quality of life, and mortality. HAND typically improves with antiretroviral therapy (ART) against HIV, but the improvement is often incomplete. There are over 20 antiretroviral medications approved in the United States, but it is not clear if specific antiretroviral medications are more effective for individuals with HAND.
The purpose of this study is to investigate the neurocognitive and biomarker effect of adding zidovudine (versus placebo) to a standard of care regimen (raltegravir/tenofovir/emtricitabine) in antiretroviral-naïve subjects as well as treatment experienced subjects who have been off therapy for at least 9 months with HAND in a small precursor clinical study of 46 subjects.
Subjects randomized to either addition of zidovudine or placebo to a standard ARV regimen (raltegravir/truvada).
Who can participate?
We are seeking adults off ARV for at least 9 months with any degree of memory symptoms and with no major other diseases that would affect memory.